JP2018525021A5 - - Google Patents

Download PDF

Info

Publication number
JP2018525021A5
JP2018525021A5 JP2018511085A JP2018511085A JP2018525021A5 JP 2018525021 A5 JP2018525021 A5 JP 2018525021A5 JP 2018511085 A JP2018511085 A JP 2018511085A JP 2018511085 A JP2018511085 A JP 2018511085A JP 2018525021 A5 JP2018525021 A5 JP 2018525021A5
Authority
JP
Japan
Prior art keywords
domain
pharmaceutical composition
btx
fusion protein
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018511085A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525021A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/049106 external-priority patent/WO2017035508A1/en
Publication of JP2018525021A publication Critical patent/JP2018525021A/ja
Publication of JP2018525021A5 publication Critical patent/JP2018525021A5/ja
Pending legal-status Critical Current

Links

JP2018511085A 2015-08-27 2016-08-26 疼痛の治療を目的とする組成物及び方法 Pending JP2018525021A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562210610P 2015-08-27 2015-08-27
US62/210,610 2015-08-27
PCT/US2016/049106 WO2017035508A1 (en) 2015-08-27 2016-08-26 Compositions and methods for treatment of pain

Publications (2)

Publication Number Publication Date
JP2018525021A JP2018525021A (ja) 2018-09-06
JP2018525021A5 true JP2018525021A5 (https=) 2019-10-03

Family

ID=58101095

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018511085A Pending JP2018525021A (ja) 2015-08-27 2016-08-26 疼痛の治療を目的とする組成物及び方法
JP2018510813A Pending JP2018530315A (ja) 2015-08-27 2016-08-26 疼痛の治療を目的とする組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018510813A Pending JP2018530315A (ja) 2015-08-27 2016-08-26 疼痛の治療を目的とする組成物及び方法

Country Status (11)

Country Link
US (4) US10704035B2 (https=)
EP (2) EP3341392A4 (https=)
JP (2) JP2018525021A (https=)
KR (2) KR20180070563A (https=)
CN (2) CN108350039A (https=)
AU (2) AU2016312685A1 (https=)
BR (2) BR112018003782A2 (https=)
CA (2) CA2994729A1 (https=)
EA (1) EA201890587A1 (https=)
MX (1) MX2018002183A (https=)
WO (2) WO2017035507A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220354962A1 (en) * 2015-05-12 2022-11-10 The Trustees Of The University Of Pennsylvania Rapid production of bispecific antibodies from off-the-shelf iggs with high yield and purity
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
BR112018003782A2 (pt) 2015-08-27 2018-09-25 Ipsen Pharma Sas composições e métodos para o tratamento da dor
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3481852B1 (en) * 2016-07-08 2022-12-07 Children's Medical Center Corporation A novel botulinum neurotoxin and its derivatives
WO2019067815A2 (en) * 2017-09-29 2019-04-04 Children's Medical Center Corporation NEUROTOXIN-LIKE TOXIN AND USES THEREOF
TWI822723B (zh) 2018-01-29 2023-11-21 英商艾普森生物製藥有限公司 非神經元性 SNARE 裂解的肉毒桿菌神經毒素、裂解 hSNAP-23 之活體外方法、及經修飾 BoNT/A L 鏈蛋白酶之用途
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
CA3101481A1 (en) * 2018-05-30 2019-12-05 The Governing Council Of The University Of Toronto Methods and kits for identifying a protein associated with receptor-ligand interactions
EP3825333A4 (en) * 2018-07-06 2022-04-06 Abmax Biopharmaceuticals LOW FUNCTIONALITY ADCC/CDC MONOCLONAL ANTIBODY, METHOD FOR PREPARATION AND USE
WO2020024002A1 (en) * 2018-07-31 2020-02-06 Snoretox Pty Ltd Pegylated tetanus neurotoxins and treatment of hypotonia
WO2020116686A1 (ko) * 2018-12-06 2020-06-11 고려대학교 산학협력단 인간 항-antxr 키메라 항원 수용체 및 이의 용도
EP4093434A4 (en) * 2020-01-21 2024-06-26 Trustees of Dartmouth College Immunologically optimized botulinum toxin light chain variants
EP4100038A4 (en) 2020-02-03 2024-02-28 Premas Biotech Private Limited RECOMBINANT EXPRESSION PLATFORM, CONSTRUCTS AND METHODS FOR EXPRESSING HARD-TO-EXPRESS PROTEINS (DTE-PS)
WO2021173916A1 (en) * 2020-02-27 2021-09-02 President And Fellows Of Harvard College Nociceptor neurons control cancer immunosurveillance
GB202104294D0 (en) * 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
KR102728382B1 (ko) * 2022-10-12 2024-11-14 주식회사 알케미어 보툴리눔 독소의 경쇄 변이체
CN120699106A (zh) * 2024-03-26 2025-09-26 广州锡滔生物医药科技有限公司 一种多肽及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
EP0866718A1 (en) 1995-12-13 1998-09-30 President And Fellows Of Harvard College Use of toxin peptides and/or affinity handles for the delivering compounds into cells
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
US6767896B1 (en) 1999-01-29 2004-07-27 Cognetix, Inc. Conotoxin peptides
ATE348178T1 (de) * 1999-08-25 2007-01-15 Allergan Inc Aktivierbare rekombinante neurotoxine
AU771632B2 (en) * 1999-09-24 2004-04-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors
WO2001049312A2 (en) 1999-12-30 2001-07-12 University Of Utah Research Foundation O-superfamily conotoxin peptides
JP2006507800A (ja) * 2002-06-07 2006-03-09 ラージ・スケール・バイオロジー・コーポレイション 可撓性ワクチンアセンブリおよびワクチン送達プラットフォーム
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
WO2006096515A2 (en) 2005-03-04 2006-09-14 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
ATE518882T1 (de) 2005-09-19 2011-08-15 Allergan Inc Mit clostridientoxin aktivierbare clostridientoxine
JP2009514545A (ja) 2005-11-08 2009-04-09 アテリス ラボラトリーズ μ−コノトキシンぺプチドおよびμ−コノトキシンぺプチドの局所麻酔薬としての使用
EP2001902B1 (en) 2006-03-14 2013-03-27 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
AU2007272515B2 (en) 2006-07-11 2013-09-26 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
WO2008008805A2 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
US9284358B2 (en) 2006-07-18 2016-03-15 University Of Utah Research Foundation Conotoxin peptides
WO2012096926A2 (en) 2011-01-10 2012-07-19 President And Fellows Of Harvard College Method for delivering agents into cells using bacterial toxins
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
CA2865243A1 (en) 2012-02-23 2013-08-29 President And Fellows Of Harvard College Modified microbial toxin receptor for delivering agents into cells
WO2013177231A1 (en) 2012-05-21 2013-11-28 Massachusetts Institute Of Technology Translocation of non-natural chemical entities through anthrax protective antigen pore
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
WO2014088928A1 (en) 2012-12-03 2014-06-12 President And Fellows Of Harvard College Methods for making targeted protein toxins by sortase-mediated protein ligation
GB201407525D0 (en) 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
BR112018003782A2 (pt) 2015-08-27 2018-09-25 Ipsen Pharma Sas composições e métodos para o tratamento da dor

Similar Documents

Publication Publication Date Title
JP2018525021A5 (https=)
US11104892B2 (en) Compositions and methods for treatment of pain
JP7819168B2 (ja) 外因性活性化ループを含むクロストリジウム神経毒
US10744190B2 (en) Method for suppressing spasmodic torticollis
JP2018530315A5 (https=)
US7491799B2 (en) Modified botulinum neurotoxins
US6776990B2 (en) Methods and compositions for the treatment of pancreatitis
JP4818565B2 (ja) ロイシンベースモチーフおよびクロストリジウム神経毒
EP3998077B1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
US20060211619A1 (en) Multivalent clostridial toxin derivatives and methods of their use
Futaki et al. Arginine carrier peptide bearing Ni (II) chelator to promote cellular uptake of histidine-tagged proteins
TW201718627A (zh) 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
CN105492074A (zh) 瘙痒的抑制
TWI857985B (zh) 胜肽之結合物及其製造方法
JP2024510786A (ja) 外来性の活性化ループを含むクロストリジウム神経毒素
RU2801120C2 (ru) Меченные сортазой нейротоксины клостридий
CN120282979A (zh) 包含活化内体蛋白酶裂解位点的梭菌神经毒素
Foran 9 Use of Neurotoxins as Drug Delivery Systems
HK1261168A1 (zh) 用於治疗疼痛的组合物和方法